



IDP2Biomed
Bringing Intrinsically Disordered
Proteins to Biomedical Applications

Grant Agreement Number: 101160233

AGENDA

Technology Transfer Benchmarking in DZNE

Task 4.2: Sharing of best practices for Technology Transfer

Work Package

WP4 - Developing Research and Innovation management

Funded by the European Union. HORIZON WIDERA 2023 IDP2Biomed - grant agreement No 101160233



Funded by
the European Union

Document Information	
Document title	Technology Transfer Benchmarking in DZNE
Date	22-23 September 2025
Task Lead	DZNE
Type	Agenda
Task number	4.2
Meeting type	personally in Bonn, Technology Transfer Office of DZNE
Participants	Lars Krueger, Patrick Wunderlich, Nàdia Villacampa, Dennis de Coninck, Coline Tymister, Dániel Magyar, Andrea Gyöngyvér Bodor, Judit Katalin Kacs Kovics-Bucsi; Julianna Bárányiné Németh; Balázs Erdei

Document History			
Partner	Date	Comments	Version
ELTE - Julianna Bárányiné Németh	22 May 2025	1st draft	v1.0
ELTE - Julianna Bárányiné Németh	29 August 2025	2nd draft	v2.0

Task 4.2 description

In this task, ELTE staff members will be seconded to Technology Transfer Office of DZNE to see first-hand how their office works and to bring the most successful practices to ELTE. A 3-5 days visit is planned for the ELTE staff to be trained by this partner in transferable skills, related to technology transfer, licensing and liaison with industry

Monday 22/09/2025	
09:00 - 18:00	
Location: Venusberg-Campus 1/99 in 53127 Bonn, room: A.0.195	
09:00 - 09:15	Welcome and introduction round
09:15 - 10:15	Eötvös Loránd University introduction
10:15 - 11:00	Introduction to DZNE and Technology Transfer Office
11:00 - 12:00	Walk through the DZNE building
12:00 - 13:00	Lunch at the DZNE canteen
13:00 - 15:00	Exchange on questions from Innovation Center
15:00 - 15:30	Break
15:30 - 17:30	Exchange on questions from Industrial Relations Center
17:30 - 18:00	Summary and feedback

19:00 Joint Dinner at the Brauhaus Bönnsch, Sterntorbrücke 4, 53111 Bonn

Tuesday 23/09/2025	
09:00 - lunch time	
Location: Venusberg-Campus 1/99 in 53127 Bonn, room: A.0.195	
09:00 - 11:00	Exchange on questions from DZNE Technology Transfer Office
11:00 - 11:30	Introduction into DZNE's internal funding program
11:30 - 12:00	Summary and feedback
12:00 - 13:00	Lunch at the DZNE canteen

Funded by the European Union. HORIZON WIDERA 2023
IDP2Biomed - grant agreement No 101160233



Funded by
the European Union

Our questions:

Innovation Center's question

From our side (Innovation Center) we would be interested in the topics like:

- financing of drug development process (Phase 1, Phase 2)
- conditions of sublicensing in a licensing agreement with a third party
- tools/activities for raising the number of invention disclosures at DZNE
- methods of invention evaluation at DZNE
- experiences with different IT tools at DZNE (AI, softwares like Global Data, Inteum, Firstignite, PatSnap,...)

Related to the activities of the Faculty of Science Research and Industrial Relations Center (it is a faculty organizational unit supporting faculty innovation and technology transfer processes) I am interested in the following topics:

- What areas does research support in your institution include?
- What forms of cooperation do you have with industrial partners?
- How your organisation try to build relationships with new industrial partners?
- Related to cooperation with industrial partners, what internal services do you provide and what support do you give to your researchers?
- What practices and tools do you use to prepare your colleagues for successful cooperation with industrial partners?
- What kind of internal training do you organize for researchers in relation to technology transfer?
- How are researchers incentivized toward commercialization? (Motivational tools, integration into performance evaluation).
- What are the main problems that arise in relationships with industrial partners, and what are your best practices for dealing with them?
- In the case of RandD services, how is it handled when the partner claims all IP rights? In such cases, is this IP evaluated?
- What is your methodology for evaluating intellectual property?

Additional topics suggested by DZNE:

- What key indicators are used to measure transfer / innovation performance?
- How do you evaluate the value of data (an invention)?
- Do you have experience with company builders? Are you actively involved in team building for spin-offs? Do you take equity in spin-offs and if yes, which structures have you established to support this process?
- Do you see differences in the life science field in comparison to other research areas?
- Do you have a central budget for patenting costs or is it covered by the research groups?

